Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Daiichi Sankyo S/Adr (OP:DSNKY)

19.07 UNCHANGED

Streaming Delayed Price Updated: 3:58 PM EST, Feb 18, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	14,000
Open	19.07
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	19.07
Today's Range	19.07 - 19.07
52wk Range	17.80 - 28.21
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally

November 07, 2025

The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results...

Via MarketMinute

FDA Approves AstraZeneca And Daiichi Sankyo's Datroway For EGFR-Mutated Lung Cancer ↗

June 24, 2025

FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response rate and a $45 million milestone due.

Via Benzinga

Performance

YTD	-10.8%	-10.8%
1 Month	-7.1%	-7.1%
3 Month	-15.7%	-15.7%
6 Month	-27.5%	-27.5%
1 Year	-19.8%	-19.8%

More News

AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients ↗

April 21, 2025

Via Benzinga

DSNKY Stock Earnings: Daiichi Sankyo Co Reported Results for Q1 2024 ↗

August 13, 2024

Via InvestorPlace

Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed ↗

March 21, 2025

Via Benzinga

FDA Approves AstraZeneca, Daiichi Sankyo's Enhertu For Certain Type Of Breast Cancer Patients ↗

January 28, 2025

Via Benzinga

FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients ↗

January 21, 2025

Via Benzinga

After Lung Cancer Approval, AstraZeneca's Imfinzi Goes Under FDA Priority Review For Bladder Cancer ↗

December 06, 2024

Via Benzinga

Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients ↗

September 23, 2024

Via Benzinga

Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study ↗

September 17, 2024

Via Benzinga

AstraZeneca's Investigational Cancer Drug Disappoints In Late-Stage Lung Cancer Trial ↗

September 10, 2024

Via Benzinga

Is Merck Stock Undervalued After Its Colossal Earnings Growth?

September 07, 2024

Via MarketBeat

Recession-Resilient Asian Stock Picks: TSMC, SK Hynix Among This Analyst's Top 10 ↗

August 07, 2024

Via Benzinga

Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs Bites Into Annual Profit Forecast ↗

July 30, 2024

Via Benzinga

The 3 Most Undervalued Nasdaq 100 Stocks to Buy in July 2024 ↗

July 15, 2024

Via InvestorPlace

FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug ↗

June 27, 2024

Via Benzinga

Why Is AstraZeneca Stock Trading Lower On Tuesday? ↗

May 28, 2024

Via Benzinga

DSNKY Stock Earnings: Daiichi Sankyo Co Reported Results for Q3 2023 ↗

April 30, 2024

Via InvestorPlace

Double Good News For AstraZeneca's Breast Cancer Drugs ↗

April 29, 2024

Via Benzinga

AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor ↗

April 08, 2024

Via Benzinga

What's Going On With Pfizer Stock Today? ↗

January 25, 2024

Via Benzinga

Why Pharmaceutical Company Esperion Therapeutics Shares Are Diving Today ↗

January 03, 2024

Via Benzinga

Japan Emerges As Promising 2024 Investment Destination: 3 Stocks To Consider ↗

December 20, 2023

Via Benzinga

Merck Just Made a Big Move -- but Will It Be Enough for Investors Right Now? ↗

October 31, 2023

Via The Motley Fool

Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting ↗

September 22, 2023

Via Benzinga

Frequently Asked Questions

Is Daiichi Sankyo S/Adr publicly traded?

Yes, Daiichi Sankyo S/Adr is publicly traded.

What exchange does Daiichi Sankyo S/Adr trade on?

Daiichi Sankyo S/Adr trades on the OTC Traded

What is the ticker symbol for Daiichi Sankyo S/Adr?

The ticker symbol for Daiichi Sankyo S/Adr is DSNKY on the OTC Traded

What is the current price of Daiichi Sankyo S/Adr?

The current price of Daiichi Sankyo S/Adr is 19.07

When was Daiichi Sankyo S/Adr last traded?

The last trade of Daiichi Sankyo S/Adr was at 02/18/26 03:58 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.